Davita Inc vs Lockheed Martin Corporation — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Lockheed Martin Corporation trades at $508.37 (market cap $115.22B). The key difference: Lockheed Martin Corporation is far larger — about 10.2× Davita Inc's market cap, and Lockheed Martin Corporation pays a 2.76% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Lockheed Martin Corporation for 86 Days on average.
| DVA | LMT | |
|---|---|---|
Market Cap | $11.28B | $115.22B |
Volume | 650,294 | 1,073,075 |
Sector | Health | Industrials |
52-Week High | $240.96 | $676.70 |
52-Week Low | $103.87 | $439.19 |
Typical Hold Time | 113 Days | 86 Days |
Enterprise Value | $24.00B | $131.96B |
Dividend Yield | — | 2.76% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Lockheed Martin (LMT) trades at $507.89, down 0.44% on the day, with a bearish technical signal driven by moving averages. The stock shows strong profitability with an 8.16% net margin and 89.16% ROE, but recent earnings missed expectations in two of the last three quarters. Revenue growth is steady, projected to reach $77B in 2026, while analyst sentiment remains positive with a $645.50 consensus price target. Recent news highlights dividend increases and AI integration initiatives.
The outlook for LMT is supported by robust defense spending and a high analyst buy rating (59%), but risks include fixed-price contract volatility and debt levels. The stock offers a dividend yield near 0.7% with 23 consecutive years of increases. Upside potential exists if earnings rebound, though technical resistance near $510 may cap near-term gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →